Allaeys Toon, Berzenji Lawek, Lauwers Patrick, Yogeswaran Suresh Krishan, Hendriks Jeroen M H, Billiet Charlotte, De Bondt Charlotte, Van Schil Paul E
Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.
Department of Radiation Oncology, Iridium Network, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium.
Cancers (Basel). 2022 Mar 25;14(7):1656. doi: 10.3390/cancers14071656.
For patients with locally advanced non-small cell lung cancer (NSCLC) or positive N1 nodes, multimodality treatment is indicated. However, the optimal management of patients presenting with ipsilateral positive mediastinal nodes (N2 disease) has not been determined yet. Different treatment regimens consisting of chemotherapy, radiation therapy, and surgery have been proposed and implemented previously. In more recent years, immunotherapy and targeted therapies have been added as therapeutic options. The role of surgery is currently redefined. Recent studies have shown that surgical resection after induction immunotherapy or targeted therapy is feasible and yields good short-term results. In this review, we summarize the latest data on multimodality treatment options for stage IIIA-N2 locally advanced NSCLC, depending on the extent of nodal involvement.
对于局部晚期非小细胞肺癌（NSCLC）或N1淋巴结阳性的患者，建议采用多模式治疗。然而，同侧纵隔淋巴结阳性（N2期疾病）患者的最佳治疗方案尚未确定。此前已提出并实施了由化疗、放疗和手术组成的不同治疗方案。近年来，免疫疗法和靶向疗法也已成为治疗选择。目前手术的作用正在重新定义。最近的研究表明，诱导免疫疗法或靶向疗法后的手术切除是可行的，并且能产生良好的短期效果。在本综述中，我们根据淋巴结受累程度，总结了IIIA-N2期局部晚期NSCLC多模式治疗方案的最新数据。
